Enlivex Annouces Participation in A.G.P.’s Upcoming 2021 Virtual Summer Healthcare Symposium

Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in A.G.P.’s Virtual Summer Healthcare Symposium on June 17, 2021. The event includes 1-on-1 virtual meetings with investors interested in the company’s management team.

Enlivex is developing Allocetra™ as a universal cell therapy aimed at reprogramming macrophages to restore their homeostatic state, potentially addressing various serious conditions, including solid cancers and COVID-19.

Positive

• Participation in a notable healthcare symposium can enhance investor relations and visibility.
• The development of Allocetra™ and its innovative approach to macrophage reprogramming could lead to significant advancements in immunotherapy.

Negative

• None.

Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.

The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are interested in meeting with members of Enlivex’s management team should contact their A.G.P. representative.

ABOUT ALLOCETRA^TM

Allocetra^TM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra^TM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.

ABOUT ENLIVEX

Enlivex is a clinical stage immunotherapy company developing Allocetra^TM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA^TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com

 

FAQ

What is ENLV's participation in the A.G.P. Summer Healthcare Symposium?

Enlivex Therapeutics Ltd. will participate in the A.G.P.’s Virtual Summer Healthcare Symposium on June 17, 2021, facilitating virtual meetings with investors.

What is Allocetra™ developed by Enlivex?

Allocetra™ is a universal cell therapy designed to reprogram macrophages into their homeostatic state, targeting severe conditions like cancers and COVID-19.

When is the A.G.P. Summer Healthcare Symposium?

The A.G.P. Summer Healthcare Symposium is scheduled for June 17, 2021.

What are the potential applications of Allocetra™?

Allocetra™ has potential applications in treating solid cancers, sepsis, COVID-19, and other diseases by restoring macrophage homeostasis.